T cell growth control using hapten-specific antibody/interleukin-2 receptor chimera

Cytokine

Volumn 46, Issue 1, 2009, Pages 127-136

  Sogo, Takahiro ^a   Kawahara, Masahiro ^a   Ueda, Hiroshi ^a   Otsu, Makoto ^b   Onodera, Masafumi ^c   Nakauchi, Hiromitsu ^b   Nagamune, Teruyuki ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b THE UNIVERSITY OF TOKYO   (Japan)

^c NATIONAL RESEARCH INSTITUTE FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

Author keywords

Chimeric receptor; Growth control; Interleukin 2 receptor; Single chain Fv; T cell

Indexed keywords

ANTIBODY CONJUGATE; BOVINE SERUM ALBUMIN; CHIMERIC PROTEIN; ERYTHROPOIETIN RECEPTOR; HAPTEN ANTIBODY; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR BETA; INTERLEUKIN 2 RECEPTOR GAMMA; INTERLEUKIN 3; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; STAT3 PROTEIN; STAT5 PROTEIN;

ANIMAL CELL; ARTICLE; CELL EXPANSION; CELL GROWTH; CONCENTRATION RESPONSE; CONTROLLED STUDY; GENE EXPRESSION; GENETIC TRANSFECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; SIGNAL TRANSDUCTION; T LYMPHOCYTE; WILD TYPE;

ANIMALS; CELL LINE; DIMERIZATION; FLOW CYTOMETRY; HAPTENS; INTERLEUKIN-3; LIGANDS; MICE; MODELS, BIOLOGICAL; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, INTERLEUKIN-2; RECOMBINANT FUSION PROTEINS; RETROVIRIDAE; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

MURINAE;

EID: 62749198592     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2008.12.020     Document Type: Article

References (42)

1. Stauber D.J., Debler E.W., Horton P.A., Smith K.A., and Wilson I.A. Crystal structure of the IL-2 signaling complex: paradigm for a heterotrimeric cytokine receptor. Proc Natl Acad Sci USA 103 (2006) 2788-2793
2. c receptors. Science 310 (2005) 1159-1163
3. Nelson B.H., Lord J.D., and Greenberg P.D. Cytoplasmic domains of the interleukin-2 receptor beta and gamma chains mediate the signal for T-cell proliferation. Nature 369 (1994) 333-336
4. Leen A.M., Rooney C.M., and Foster A.E. Improving T cell therapy for cancer. Annu Rev Immunol 25 (2007) 243-265
5. Knutson K.L., Almand B., Mankoff D.A., Schiffman K., and Disis M.L. Adoptive T-cell therapy for the treatment of solid tumours. Exp Opin Biol Ther 2 (2002) 1-12
6. Rosenberg S.A. Progress in human tumour immunology and immunotherapy. Nature 411 (2001) 380-384
7. Tey S.K., Bollard C.M., and Heslop H.E. Adoptive T-cell transfer in cancer immunotherapy. Immunol Cell Biol 84 (2006) 281-289
8. Cheever M.A., and Chen W. Therapy with cultured T cells: principles revisited. Immunol Rev 157 (1997) 177-194
9. Dudley M.E., and Rosenberg S.A. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 3 (2003) 666-675
10. Dudley M.E., Wunderlich J.R., Yang J.C., Sherry R.M., Topalian S.L., Restifo N.P., et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23 (2005) 2346-2357
11. Koike N., Pilon-Thomas S., and Mule J.J. Nonmyeloablative chemotherapy followed by T-cell adoptive transfer and dendritic cell-based vaccination results in rejection of established melanoma. J Immunother 31 (2008) 402-412
12. Kragel A.H., Travis W.D., Feinberg L., Pittaluga S., Striker L.M., Roberts W.C., et al. Pathologic findings associated with interleukin-2-based immunotherapy for cancer: a postmortem study of 19 patients. Hum Pathol 21 (1990) 493-502
13. Rosenberg S.A., Lotze M.T., Muul L.M., Leitman S., Chang A.E., Ettinghausen S.E., et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313 (1985) 1485-1492
14. Kawahara M., Ueda H., Morita S., Tsumoto K., Kumagai I., and Nagamune T. Bypassing antibiotic selection: positive screening of genetically modified cells with an antigen-dependent proliferation switch. Nucleic Acids Res 31 (2003) e32
15. Kawahara M., Kimura H., Ueda H., and Nagamune T. Selection of genetically modified cell population using hapten-specific antibody/receptor chimera. Biochem Biophys Res Commun 315 (2004) 132-138
16. Ueda H., Kawahara M., Aburatani T., Tsumoto K., Todokoro K., Suzuki E., et al. Cell-growth control by monomeric antigen: the cell surface expression of lysozyme-specific Ig V-domains fused to truncated Epo receptor. J Immunol Methods 241 (2000) 159-170
17. Sogo T., Kawahara M., Tsumoto K., Kumagai I., Ueda H., and Nagamune T. Selective expansion of genetically modified T cells using an antibody/interleukin-2 receptor chimera. J Immunol Methods 337 (2008) 16-23
18. Kawahara M., Ogo Y., Ueda H., and Nagamune T. Improved growth response of antibody/receptor chimera attained by the engineering of transmembrane domain. Protein Eng Des Sel 17 (2004) 715-719
19. Kaneko E., Kawahara M., Tsumoto K., Kumagai I., Ueda H., and Nagamune T. Antigen-mediated genetically modified cell amplification (AMEGA) with single vector transduction. J Chem Eng Japan 37 (2004) 1259-1264
20. Palacios R., and Steinmetz M. IL3-dependent mouse clones that express B-220 surface antigen, contain Ig genes in germ-line configuration, and generate B lymphocyte in vivo. Cell 41 (1985) 727-734
21. Gillis S., and Smith K.A. Long term culture of tumour-specific cytotoxic T cells. Nature 268 (1977) 154-156
22. Brielmeier M., Bechet J., Falk M.H., Pawlita M., Polack A., and Bornkamm G.W. Improving stable transfection efficiency: antioxidants dramatically improve the outgrowth of clones under dominant marker selection. Nucleic Acids Res 26 (1998) 2082-2085
23. Morita S., Kojima T., and Kitamura T. Plat-E: an efficient and stable system for transient packaging of retroviruses. Gene Ther 7 (2000) 1063-1066
24. Ellery J.M., and Nicholls P.J. Alternate signaling pathways from the interleukin-2 receptor. Cytokine Growth Factor Rev 13 (2002) 27-40
25. Asao H. Mechanism of interleukin 2-induced signal transduction. Yamagata Med J 21 (2003) 141-154
26. Jiang K., Zhong B., Ritchey C., Gilvary D.L., Hong-Geller E., Wei S., et al. Regulation of Akt-dependent cell survival by Syk and Rac. Blood 101 (2003) 236-244
27. + T cells of human IL-2 receptor beta-chain transgenic mice. J Immunol 153 (1994) 5373-5381
28. high but not other T cells. J Immunol 164 (2000) 5659-5667
29. Nishi M., Ishida Y., and Honjo T. Expression of functional interleukin-2 receptors in human light chain/Tac ransgenic mice. Nature 331 (1988) 267-269
30. Nakamura Y., Russell S.M., Mess S.A., Friedmann M., Erdos M., Francois C., et al. Heterodimerization of the IL-2 receptor beta- and gamma-chain cytoplasmic domains is required for signalling. Nature 369 (1994) 330-333
31. Onishi M., Nosaka T., Misawa K., Mui A.L.-F., Gorman D., McMahon M., et al. Identification and characterization of a constitutively active STAT5 mutant that promotes cell proliferation. Mol Cell Biol 18 (1998) 3871-3879
32. Goldsmith M.A., Amaral M.C., and Greene W.C. Ligand binding by the IL-2 receptor is modulated by intracellular determinants of the IL-2 receptor β-chain. J Immunol 154 (1995) 2033-2040
33. Ellery J.M., and Nicholls P. Possible mechanism for the alpha subunit of the interleukin-2 receptor (CD25) to influence interleukin-2 receptor signal transduction. Immunol Cell Biol 80 (2002) 351-357
34. Cooper L.J.N., Ausubel L., Gutierrez M., Stephan S., Shakeley R., Olivares S., et al. Manufacturing of gene-modified cytotoxic T lymphocytes for autologous cellular therapy for lymphoma. Cytotherapy 8 (2006) 105-117
35. + regulatory T cells in cancer patients. Blood 107 (2006) 2409-2414
36. + T cells. Nat Immunol 8 (2007) 1353-1362
37. + T-cell pool and tumor trafficking in patients with ovarian carcinoma. Cancer Res 67 (2007) 7487-7494
38. Mule J.J., Shu S., Schwarz S.L., and Rosenberg S.A. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science 225 (1984) 1487-1489
39. - tumor cells. Blood 92 (1998) 4248-4255
40. Suzuki A., Obi K., Urabe T., Hayakawa H., Yamada M., Kaneko S., Onodera M., Mizuno Y., and Mochizuki H. Feasibility of ex vivo gene therapy for neurological disorders using the new retroviral vector GCDNsap packaged in the vesicular stomatitis virus G protein. J Neurochem 82 (2002) 953-960
41. Kaneko S., Nagasawa T., Nakauchi H., and Onodera M. An in vivo assay for retrovirally transduced human peripheral T lymphocytes using nonobese diabetic/severe combined immunodeficiency mice. Exp Hematol 33 (2005) 35-41
42. Sanuki S., Hamanaka S., Kaneko S., Otsu M., Karasawa S., Miyawaki A., Nakauchi H., Nagasawa T., and Onodera M. A new red fluorescent protein that allows efficient marking of murine hematopoietic stem cells. J Gene Med 10 (2008) 965-971